Dartmouth-Hitchcock logo
Medicine Grand Rounds - The Monoclonal Antibodies and Headache

Dr. Tepper discusses the unmet clinical needs resulting from ineffective preventive treatment in migraine and how the new anti-CGRP therapies appear more effective and better tolerated than previous treatments. He describes the pivotal role that CGRP plays in the pathophysiology of migraine headaches and how targeted CGRP therapies (including Monoclonal Antibodies) offer a novel therapeutic approach to the treatment of migraine headache disorders. Dr Tepper reviews current evidence regarding safety and efficacy of these drugs in parallel with a consideration of their implications for improvement in quality of life and productivity across a wide spectrum of clinical scenarios previously considered treatment refractory.

Activity Details

Start Date:   August 23, 2019
End Date:   August 23, 2021

You may claim CME credit for successful completion of this online course. In order to claim credit, you must follow these steps:

  1. Register for the learning activity by creating an account or logging in to your account.
  2. Click Continue to navigate to the Activity Material tab. Click View Presentation to view the recording. View the entire presentation.
  3. Return to this Activity page.
  4. Click Continue to navigate to the Evaluation tab; then click the Launch button to start the evaluation.
  5. Complete and Submit the evaluation and attestation form.

When the evaluation is submitted, you will be awarded credit. You may access your transcript for verification of participation at any time via Your Account. Need help? Visit the Support Page, send an Email, or call the Center for Learning and Professional Development at (603) 653-1234, Option 1.

  • Stewart J. Tepper, MD, FAHS
    Professor of Neurology
    Geisel School of Medicine at Dartmouth-Hitchcock
    Director, Dartmouth Headache Center
    Dartmouth-Hitchcock Medical Center

    Stewart J. Tepper, MD received his undergraduate degree in the study of the nervous system/ psychobiology from Yale College, New Haven, Connecticut, and attended Cornell University Medical College in New York City. He completed his Neurology residency at Harvard Medical School in Boston, Massachusetts, and has been board certified in Headache Medicine since 2006.

    Dr. Tepper is the Editor-in-Chief of the journal Headache Currents and Associate Editor for the journal Headache. Dr. Tepper serves on the Board of Directors of the American Headache Society.

Learning Outcome

Participants will be able to identify the unmet clinical needs resulting from ineffective preventive treatments in migraines, analyze the role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology, discuss the efficacy and safety of emerging treatments, and identify patients who might benefit from preventive treatment with anti-CGRP monoclonal antibodies.


Dartmouth-Hitchcock is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Dartmouth-Hitchcock designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Requirements for Successful Completion

In order to receive credit for this Continuing Medical Education (CME) activity, you must:

  • View the entire presentation
  • Complete the online Attestation of Attendance & Evaluation Form (you must register to access).

In accordance with the disclosure policy of Dartmouth-Hitchcock/Geisel School of Medicine at Dartmouth as well as standards set forth by the Accreditation Council on Continuing Medical Education and the Nursing Continuing Education Council standards set forth by the American Nurses Credentialing Center Commission on Accreditation, continuing medical education and nursing education activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content have been asked to disclose any financial relationship* they have to a commercial interest (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients). Such disclosure is not intended to suggest or condone bias in any presentation, but is elicited to provide participants with information that might be of potential importance to their evaluation of a given activity.

The following Activity Physician Director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for The Monoclonal Antibodies and Headache (Medicine Grand Rounds) have reported the following financial interest or relationship* with various companies/organizations. The Activity Director and Planning Committee member roles were resolved by altering the individual’s control over content about the products or services of the commercial interest by the Associate Dean for CME and the Department of Medicine Chair. The speaker role was resolved by validating the activity content through independent peer review by Kelly Kieffer, MD. All potential conflict(s) were resolved.

* Kelly Kieffer, MD ~ her spouse is a consultant for OcculoBio. 

* Richard I. Rothstein, MD ~ has research support from Baranova (research grant to Dartmouth-Hitchcock Medical Center) and has other financial interest from Allurion. 

* Stewart J. Tepper, MD, FAHS ~ has grant/research support from Alder, Allergan, Amgen, ATI, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura,, Neurolief, Novartis, Scion Neurostim, Teva, and Zosano.

He is a consultant for ATI, Axsome Therapeutics, BioDelivery Sciences International, Biohaven, Charleston Labs, Decision Resources, DeepBench, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, ExpertConnect, GLG, GSK, Guidepoint Global, Impel, M3 Global Research, Magellan Rx Management, Marcia Berenson Connected Research and Consulting, Medicxi, Navigant Consulting, Neurolief, Nordic BioTech, Novartis, Pfizer, Reckner Healthcare, Relevale, Satsuma, Scion Neurostim, Slingshot Insights, Sorrento, Spherix Global Insights, Sudler and Hennessey, Teva, Theranica, Thought Leader Select, Trinity Partners, XOC, and Zosano.

He receives an editorship salary for the American Headache Society publication.

Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this program report no financial interest or relationship* with any company(ies) or organizations whose product may be germane to the content of their presentations.

*A “financial interest or relationship" refers to an equity position, receipt of royalties, consultantship, funding by a research grant, receiving honoraria for educational services elsewhere, or to any other relationship to a company that provides sufficient reason for disclosure, in keeping with the spirit of the stated policy.

Provider Contact Information

Provider contact information for questions regarding accreditation of the activity:

Center for Learning and Professional Development
Dartmouth-Hitchcock Medical Center

Type:     Internet Activity (Enduring Material)
21 Registered Users